Buprenorphine/Naloxone for Opioid Use Disorder

Last updated on August 7, 2019

This unique PAD session provides an opportunity to get answers to your questions about buprenorphine/naloxone in the treatment of opioid use disorder in a personalized 30-60 minute academic detailing session conducted via Web Conferencing at a time that is convenient for you.

This academic detailing session was co-developed with BC Centre for Substance Use and was planned to achieve scientific integrity, objectivity and balance.

Learning Objectives

The goal of this educational session is to promote the appropriate use of buprenorphine/naloxone in the management of opioid use disorder.

After the PAD educational session, participants will be able to:

Review clinical considerations for initiating and managing patients started on buprenorphine/naloxone for opioid use disorder
Describe the role of each medicinal component of the medication.
Describe the correct method for administering the medication.
List the most important drug interactions with buprenorphine/naloxone and the potential consequences.

Availability

When: Until July 31, 2019
Where: Via individual Web sessions
How: Email pad@gov.bc.ca or Phone 604 660-1978

Resources

For more information about the PAD service, see PAD Frequently Asked Questions.

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.